Index - P/E - EPS (ttm) - Insider Own 49.54% Shs Outstand 37.47M Perf Week -19.01%
Market Cap 245.80M Forward P/E - EPS next Y -2.75 Insider Trans 5.10% Shs Float 18.91M Perf Month -33.27%
Income - PEG - EPS next Q -0.78 Inst Own 0.94% Short Float 4.79% Perf Quarter -
Sales - P/S - EPS this Y 85.34% Inst Trans - Short Ratio 4.06 Perf Half Y -
Book/sh -3.62 P/B - EPS next Y 6.53% ROA - Short Interest 0.91M Perf Year -
Cash/sh 7.24 P/C 0.91 EPS next 5Y - ROE - 52W Range 5.50 - 12.74 Perf YTD -36.37%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -48.51% Beta -
Dividend TTM - Quick Ratio 4.04 Sales past 5Y 3569.20% Gross Margin - 52W Low 19.27% ATR (14) 0.79
Dividend Ex-Date - Current Ratio 4.04 EPS Y/Y TTM - Oper. Margin - RSI (14) 35.61 Volatility 12.07% 10.53%
Employees 236 Debt/Eq 0.22 Sales Y/Y TTM - Profit Margin - Recom 1.33 Target Price 18.40
Option/Short No / Yes LT Debt/Eq 0.21 EPS Q/Q - Payout - Rel Volume 0.20 Prev Close 6.32
Sales Surprise 6.89% EPS Surprise 16.72% Sales Q/Q - Earnings Mar 28 BMO Avg Volume 222.94K Price 6.56
SMA20 -16.51% SMA50 -33.71% SMA200 -35.44% Trades
Volume 24,689 Change 3.80%
Date
Action
Analyst
Rating Change
Price Target Change
May-02-24 Downgrade JP Morgan
Overweight → Neutral
$16 → $6
Mar-05-24 Initiated Wells Fargo
Overweight
$25
Mar-05-24 Initiated TD Cowen
Outperform
Mar-05-24 Initiated JP Morgan
Overweight
$16
Mar-05-24 Initiated Jefferies
Buy
$23
Mar-05-24 Initiated Chardan Capital Markets
Buy
$21
Mar-05-24 Initiated BMO Capital Markets
Outperform
$22
May-04-24 10:49AM
May-02-24 06:04AM
May-01-24 04:00PM
01:53PM
Apr-08-24 08:00AM
09:16AM
Loading…
Mar-27-24 09:16AM
Feb-29-24 04:30PM
Feb-13-24 04:35PM
Feb-08-24 10:16PM
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Novo Holdings A/S 10% Owner Feb 13 '24 Buy 15.00 800,000 12,000,000 1,739,175 Feb 15 08:38 PM Novo Holdings A/S 10% Owner Feb 09 '24 Buy 10.25 100,000 1,025,000 100,000 Feb 15 08:38 PM
Index RUT P/E - EPS (ttm) -2.63 Insider Own 6.40% Shs Outstand 54.58M Perf Week 10.36%
Market Cap 84.42M Forward P/E - EPS next Y -1.29 Insider Trans -0.62% Shs Float 51.15M Perf Month -80.19%
Income -141.41M PEG - EPS next Q -0.66 Inst Own 101.78% Short Float 8.83% Perf Quarter -84.46%
Sales 30.99M P/S 2.72 EPS this Y 16.53% Inst Trans 1.35% Short Ratio 2.46 Perf Half Y -75.48%
Book/sh 0.31 P/B 5.03 EPS next Y 41.23% ROA -65.70% Short Interest 4.52M Perf Year -82.62%
Cash/sh 2.75 P/C 0.56 EPS next 5Y 20.00% ROE -213.02% 52W Range 1.11 - 11.26 Perf YTD -85.79%
Dividend Est. - P/FCF - EPS past 5Y 6.04% ROI -125.60% 52W High -86.28% Beta 1.12
Dividend TTM - Quick Ratio 4.01 Sales past 5Y 176.17% Gross Margin 91.51% 52W Low 39.19% ATR (14) 0.42
Dividend Ex-Date - Current Ratio 4.07 EPS Y/Y TTM -520.26% Oper. Margin -424.30% RSI (14) 17.96 Volatility 6.41% 14.32%
Employees 165 Debt/Eq 6.58 Sales Y/Y TTM 21.63% Profit Margin -456.31% Recom 1.55 Target Price 8.78
Option/Short Yes / Yes LT Debt/Eq 5.71 EPS Q/Q 3.42% Payout - Rel Volume 0.81 Prev Close 1.51
Sales Surprise -10.18% EPS Surprise -18.74% Sales Q/Q 0.39% Earnings May 08 BMO Avg Volume 1.84M Price 1.54
SMA20 -49.56% SMA50 -76.94% SMA200 -80.34% Trades
Volume 809,406 Change 2.32%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Downgrade Robert W. Baird
Outperform → Neutral
$20 → $2
Apr-15-24 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$24 → $3
Aug-11-23 Downgrade Oppenheimer
Outperform → Perform
$14 → $9
Jan-20-23 Initiated RBC Capital Mkts
Outperform
$23
Sep-30-20 Initiated Truist
Buy
$35
Jul-01-20 Reiterated H.C. Wainwright
Buy
$6 → $9
Jul-01-20 Initiated Cowen
Outperform
Apr-09-20 Initiated Craig Hallum
Buy
$4.50
Dec-20-19 Initiated Oppenheimer
Outperform
Mar-05-19 Resumed Jefferies
Buy
$3.50 → $10
Feb-27-19 Downgrade Mizuho
Buy → Neutral
$13 → $5
Feb-06-19 Initiated Leerink Partners
Outperform
$10
Jul-02-18 Initiated Cantor Fitzgerald
Overweight
$19
Mar-20-18 Initiated Mizuho
Buy
$13
Feb-15-18 Initiated H.C. Wainwright
Buy
$33
Dec-14-17 Initiated Laidlaw
Buy
$18
Aug-10-16 Reiterated Jefferies
Buy
$2.50 → $3
Jun-14-16 Downgrade RBC Capital Mkts
Outperform → Sector Perform
Mar-08-16 Reiterated Stifel
Buy
$23 → $16
Dec-17-15 Initiated RBC Capital Mkts
Outperform
$14
Show Previous Ratings
May-02-24 08:00AM
May-01-24 08:00AM
Apr-16-24 11:46AM
Apr-15-24 12:54PM
11:30AM
07:00AM
Loading…
07:00AM
Apr-05-24 04:00PM
Mar-27-24 08:41AM
Mar-25-24 10:00AM
Mar-20-24 10:32AM
Mar-07-24 01:41PM
11:10AM
Mar-06-24 07:14AM
(Thomson Reuters StreetEvents)
Mar-05-24 05:10PM
04:24PM
(Associated Press Finance)
04:01PM
Loading…
04:01PM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
Feb-16-24 04:00PM
Jan-30-24 08:13PM
Jan-22-24 09:56AM
Jan-17-24 09:55AM
Jan-04-24 04:30PM
07:01AM
Dec-29-23 06:45AM
Dec-07-23 04:30PM
Nov-20-23 04:01PM
Nov-14-23 04:05PM
Nov-09-23 04:30PM
Nov-08-23 04:32PM
07:55AM
Loading…
Nov-07-23 07:55AM
07:36AM
(Associated Press Finance)
07:01AM
07:00AM
Oct-24-23 07:01AM
Oct-11-23 09:55AM
Oct-06-23 04:00PM
Sep-21-23 04:00PM
Sep-20-23 09:02AM
09:01AM
Sep-19-23 04:51PM
08:00AM
Sep-12-23 04:00PM
Sep-06-23 04:01PM
Aug-17-23 04:01PM
Aug-11-23 04:01PM
09:36AM
Aug-10-23 08:40AM
07:34AM
07:01AM
Jul-31-23 12:03PM
(American City Business Journals) +5.03%
07:01AM
Jul-27-23 07:01AM
Jul-25-23 03:48PM
Jul-13-23 04:30PM
Jul-03-23 04:23AM
Jun-21-23 04:01PM
Jun-12-23 07:59AM
Jun-02-23 04:30PM
May-26-23 08:10AM
May-17-23 04:01PM
May-16-23 11:50AM
06:01AM
May-11-23 08:35AM
07:24AM
07:01AM
May-09-23 04:01PM
May-04-23 10:00AM
May-03-23 07:01AM
Apr-27-23 07:01AM
Apr-18-23 11:03AM
07:01AM
04:30AM
Apr-06-23 04:00PM
Mar-22-23 09:01AM
Mar-08-23 12:12PM
(Thomson Reuters StreetEvents) +5.33%
Mar-07-23 05:15PM
04:01PM
Mar-06-23 04:01PM
Feb-15-23 01:00PM
10:24AM
Feb-13-23 07:15AM
Feb-10-23 04:01PM
Feb-07-23 07:15AM
Jan-30-23 04:01PM
Jan-20-23 02:17PM
Jan-09-23 04:17PM
Jan-05-23 04:01PM
Dec-30-22 12:46AM
Dec-21-22 07:20AM
Dec-09-22 04:01PM
Nov-30-22 04:01PM
Nov-18-22 09:00AM
Nov-17-22 01:47PM
(American City Business Journals)
09:17AM
07:00AM
07:00AM
Nov-10-22 12:59PM
(American City Business Journals)
07:34AM
Nov-07-22 11:12PM
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Braunstein Scott CHAIRMAN AND CEO Mar 27 '24 Option Exercise 4.28 50,000 214,000 273,512 Mar 27 11:55 AM Shafer Christina CHIEF COMMERCIAL OFFICER Feb 20 '24 Sale 9.56 2,153 20,583 60,308 Feb 22 04:05 PM MANNING MARTHA E SVP, GEN. COUNSEL & CORP. SEC. Feb 20 '24 Sale 9.57 1,894 18,126 52,966 Feb 22 04:05 PM Braunstein Scott CHAIRMAN AND CEO Feb 16 '24 Sale 9.94 11,850 117,789 223,512 Feb 21 04:05 PM Pfanstiel Steven CFO AND COO Feb 16 '24 Sale 9.97 3,092 30,827 71,697 Feb 21 04:05 PM Hulihan Joseph CHIEF MEDICAL OFFICER Feb 16 '24 Sale 9.98 2,814 28,084 66,635 Feb 21 04:06 PM Braunstein Scott CHAIRMAN AND CEO Aug 08 '23 Sale 8.94 30 268 160,762 Aug 08 09:05 PM Pfanstiel Steven CFO AND COO Aug 08 '23 Sale 8.93 14 125 49,324 Aug 08 09:05 PM Hulihan Joseph CHIEF MEDICAL OFFICER Aug 08 '23 Sale 8.93 13 116 47,614 Aug 08 09:05 PM Shafer Christina CHIEF COMMERCIAL OFFICER Aug 08 '23 Sale 8.93 11 98 40,626 Aug 08 09:05 PM MANNING MARTHA E SVP, GEN. COUNSEL & CORP. SEC. Aug 08 '23 Sale 8.93 11 98 33,025 Aug 08 09:05 PM Braunstein Scott CHAIRMAN AND CEO Aug 07 '23 Sale 9.55 6,413 61,244 160,792 Aug 08 09:05 PM Hulihan Joseph CHIEF MEDICAL OFFICER Aug 07 '23 Sale 9.55 2,889 27,590 47,627 Aug 08 09:05 PM Pfanstiel Steven CFO AND COO Aug 07 '23 Sale 9.54 2,790 26,617 49,338 Aug 08 09:05 PM Shafer Christina CHIEF COMMERCIAL OFFICER Aug 07 '23 Sale 9.52 2,385 22,705 40,637 Aug 08 09:05 PM MANNING MARTHA E SVP, GEN. COUNSEL & CORP. SEC. Aug 07 '23 Sale 9.54 2,169 20,692 33,036 Aug 08 09:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
